News Release

Patent Application Describes HemogloBind™ To Reduce Analytical Interferences 

from Hemolysis

MONMOUTH JUNCTION, NJ, January 25, 2019 -- Biotech Support Group reports on a patent application describing the describing the simplicity and efficiency of their hemoglobin depletion technology for improving bilirubin measurements. The citation is:

Krishna, Neel K., and Kenji Cunnion. "Derivative Peptide Compounds and Methods of Use." U.S. Patent Application No. 15/192,934.
http://www.freepatentsonline.com/y2016/0376322.html

The patent application describes synthetic peptide compounds for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids which is a scrambled peptide derived from human Astrovirus protein. This peptide is also known as PIC1, describing Peptide Inhibitors of Complement C1. In the example description, the patent states “Due to large amounts of hemolysis in the latter time points and the associated optical interference in bilirubin analysis, all the samples were pre-treated with HemogloBind™ (Biotech Support Group, NJ) prior to analysis with the Bilirubin Assay Kit.”

“The large amount of hemoglobin in samples of this type presents a special challenge for quantitative analysis. These articles demonstrate yet again that HemogloBind™ can reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the analyses of interest, in this case - bilirubin.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:

Matthew Kuruc
732-274-2866
mkuruc@biotechsupportgroup.com